Study to Investigate Long-term Pulmonary and Extrapulmonary Effects of COVID-19
- Conditions
- COVID-19
- Interventions
- Other: COVID-19
- Registration Number
- NCT04581135
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Brief Summary
Prospective Observational Swiss Cohort Study to Investigate Long-term Pulmonary and Extrapulmonary Effects of COVID-19.
- Detailed Description
COVID-19 is a coronavirus induced viral pneumonia leading to Acute Respiratory Distress Syndrome. Previous coronavirus infections (SARS and MERS) led to pulmonary fibrosis in up to 30%. Prospective evaluation of lung abnormalities and pulmonary fibrosis after COVID-19 infection is crucial as novel treatments against lung fibrosis of different etiologies are available. No data on pulmonary longterm effects in COVID-19 survivors are currently available. The nation-wide Swiss COVID-19 lung group establishes a meticulously characterized prospective cohort study on pulmonary long-term sequela of patients living in Switzerland.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 620
- Signed written informed consent.
- All adult patients with COVID-19 over 18 years.
- Severe mental or physical disability precluding informed consent or compliance with the protocol for prospective data collection.
- Pregnancy.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description COVID-19 Lung COVID-19 COVID-19 survivors in Switzerland
- Primary Outcome Measures
Name Time Method Pulmonary follow-up sequelae in patients after COVID-19 36 months Number of patients with the long-term pulmonary complications by measuring lung function, exercise testing and radiological Imaging
Evaluation of risk factors for adverse Outcome after COVID-19 36 months Number of patients with risk factors including comorbidities and other cofactors and correlate them to adverse outcome in patients after COVID-19
- Secondary Outcome Measures
Name Time Method Quality of Life after COVID-19 36 months Compare Quality of Life questionnaires between mild and moderate to severe and critical COVID-19 disease
Compare the functional Pulmonary outcome of COVID-19 disease 36 months Compare pulmonary function measurements between mild and moderate to severe and critical COVID-19 disease
Compare the radiological Pulmonary outcome of COVID-19 disease 36 months Compare imaging measurements between mild and moderate to severe and critical COVID-19 disease
Physical performance after COVID-19 using frailty assessment tests 36 months To observe and compare the physical performance after COVID-19 via frailty assessment tests between mild and moderate to severe and critical COVID-19 disease
Microbiota and COVID-19 36 months Number of patients with changes in microbiota in response to COVID-19 by microbiota analysis of sputa, bronchoalveolar lavage and swaps
Physical performance after COVID-19 using Clinical Frailty Scale 36 months To observe and compare the physical performance after COVID-19 via the Clinical Frailty Scale between mild and moderate to severe and critical COVID-19 disease
Trial Locations
- Locations (9)
Kantonspital St. Gallen - Klinik für Pneumologie und Schlafmedizin Lungenzentrum
🇨🇭St. Gallen, Switzerland
Hôpitaux Universitaires de Genève - Service de Pneumologie
🇨🇭Genève, Switzerland
Universtiy Hospital Bern (Inselspital), Department of Pulmonary Medicine - Lead Center
🇨🇭Bern, Switzerland
University and Hospital of Fribourg
🇨🇭Fribourg, Switzerland
St. Claraspital AG - Department of Pulmonary Medicine
🇨🇭Basel, Switzerland
CHUV - Service de Pneumologie
🇨🇭Lausanne, Switzerland
Hôpital du Valais - Service de Pneumologie
🇨🇭Sion, Switzerland
Universitätsspital Zürich - Klinik für Pneumologie
🇨🇭Zürich, Switzerland
Clinica Moncucco
🇨🇭Lugano, Switzerland